A new form of HIV vaccine is now scheduled to be trialed later this year in South Africa after satisfying standards for clinical trials to help solve the epidemic in Africa.
In 2015, Africa has been a key place to the virus, 2.1 million new cases of infections recorded – two- thirds are came from sub-Saharan Africa.
Prior to the large-scale testing to the affected areas, last year a small trial has been conducted in South Africa for the vaccine called HVTN100 in order to ensure safety and strength of immunity of the latter in the epidemic virus.
There are two-hundred and fifty -two healthy volunteers enrolled on the said vaccine, known as ALVAC-HIV/gp120, or a placebo to compare the extent of immune responses. The test results were presented at the 21st International AIDS conference held at Durban, South Africa.
“This was precautionary to see if the vaccine looks promising,” said deputy director of Desmond Tutu HIV center and president-elect of International AIDS society Linda Gail Bekker.
In 2009, when the vaccine stems first tried in Thailand that showed significant protection against HIV virus, about 31% protect of the virus.
Seven years after, a larger-scale trial of the vaccine is set to begin for 5,400 people in four sites in South Africa in November 2016 and will run for three years.
In the conference, Gail Bekker believed that the vaccine will considered as the first licensable vaccine regimen in the world.
“I don’t think we are going to treat way out of this epidemic.. we are ultimately going to need a vaccine to shut it down,” Gail Bekker said at the convention.
Experts have long been awaits a vaccine showing enough efficacy to dent the numbers of people newly infected with HIV per year, which fell by 0.7% between 2005 and 2015, based on a study presented at the conference.